tert-butyl (3S,4S)-3-(4-bromo-2-chlorophenyl)-4-(pyridin-3-yl)piperidine-1-carboxylate | 1247090-99-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl (3S,4S)-3-(4-bromo-2-chlorophenyl)-4-(pyridin-3-yl)piperidine-1-carboxylate
• 英文别名: tert-butyl (3S,4S)-3-(4-bromo-2-chlorophenyl)-4-pyridin-3-ylpiperidine-1-carboxylate
• CAS: 1247090-99-8
• 化学式: C₂₁H₂₄BrClN₂O₂
• 分子量: 451.791
• InChiKey: NFBBSQAMNHVQII-AEFFLSMTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  42.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl (3S,4S)-3-(4-bromo-2-chlorophenyl)-4-(pyridin-3-yl)piperidine-1-carboxylate 在 palladium on activated charcoal 、 氢气 、 palladium diacetate 、 sodium carbonate 、 N,N-二异丙基乙胺 、 三苯基膦 作用下， 以 甲醇 、 丙醇 、 二氯甲烷 为溶剂， 生成 tert-butyl (3S,4S)-3-{2'-[2-(acetylamino)ethyl]-3-chlorobiphenyl-4-yl}-4-(pyridin-3-yl)piperidine-1-carboxylate
  参考文献：
  名称：

  3,4-Diarylpiperidines as potent renin inhibitors

  摘要：

  The discovery and SAR of a series of potent renin inhibitors possessing a novel 3,4-diarylpiperidine scaffold are described herein. The resulting compound 38 exhibit low nanomolar plasma renin IC50, had a clean CYP 3A4 profile and displayed micromolar affinity for the hERG channel. Furthermore, it was found to be efficacious in the double transgenic rat hypertension model and show good to moderate oral bioavailability in two animal species. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.01.044
• 作为产物：
  描述：

  2-氯-4-溴苯基乙腈 在 dimethyl sulfide borane 、 硫酸 、 sodium ethanolate 、 溶剂黄146 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 为溶剂， 生成 tert-butyl (3S,4S)-3-(4-bromo-2-chlorophenyl)-4-(pyridin-3-yl)piperidine-1-carboxylate 、 (+/-)-trans-t-Butyl 3-(4-bromo-2-chlorophenyl)-4-pyridin-3-ylpiperidine-1-carboxylate
  参考文献：
  名称：

  3,4-Diarylpiperidines as potent renin inhibitors

  摘要：

  The discovery and SAR of a series of potent renin inhibitors possessing a novel 3,4-diarylpiperidine scaffold are described herein. The resulting compound 38 exhibit low nanomolar plasma renin IC50, had a clean CYP 3A4 profile and displayed micromolar affinity for the hERG channel. Furthermore, it was found to be efficacious in the double transgenic rat hypertension model and show good to moderate oral bioavailability in two animal species. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.01.044

文献信息

• RENIN INHIBITORS
  申请人：McKay Daniel J.

  公开号：US20120035214A1

  公开（公告）日：2012-02-09

  The present invention relates to biaryl piperidine-based renin inhibitor compounds, and their use in treating cardiovascular events and renal insufficiency.

  本发明涉及基于联苯哌啶的肾素抑制剂化合物及其在治疗心血管事件和肾功能不全中的应用。